Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $56.1M in Public Offering

NEW YORK (GenomeWeb News) – Fluidigm today said it has closed on its public offering of 4,209,000 shares of its common stock and raised $56.1 million in net proceeds.

The South San Francisco, Calif.-based firm announced the offering last week and priced its shares at $14.25. It plans to use proceeds for R&D, commercialization efforts, working capital, and other general corporate purposes.

Piper Jaffray and Cowen and Co, acted as joint book-running managers on the offering, while Leerink Swann, Oppenheimer, and Cantor Fitzgerald were co-managers. The underwriters exercised their over-allotment option in full to purchase 549,000 shares, Fluidigm said.

The company went public in February 2011.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.